New Delhi. NTAGI may consider allowing the use of the biological E vaccine Corbevax as a booster dose for people who have received both doses of the anti-Covid-19 Covishield or Covaccine, Whose meeting will be held on Tuesday. Sources gave this information. The Drugs Controller General of India (DCGI) on June 4 approved Corbevax for use as a precautionary dose for people aged 18 years and above. Corbevax, India’s first indigenously developed RBD protein subunit vaccine, is currently being used for children in the age group of 12 years to 14 years.
A source told PTI that the ‘National Technical Advisory Group on Immunization’ (NTAGI) will deliberate on allowing the use of Corbevax as a booster dose for people who have received either Covashield or both doses of Covaxin, Which has been approved by DCGI. This advisory committee of the government may also review the trial data of the country’s first anti-cervical cancer quadrivalent human papillomavirus (QHPV) vaccine developed by Serum Institute of India.
Sources had said that a separate HPV working group of NTAGI had on June 8 studied the clinical trial data of the vaccine and the utility of including it in the national immunization programme.
Be the first to read breaking news in Hindi News18 Hindi | Today’s latest news, live news updates, read most reliable Hindi news website News18 Hindi |
FIRST PUBLISHED : June 27, 2022, 22:11 IST